Splicing-Correcting Therapy for SMA

Cell. 2017 Jun 29;170(1):5. doi: 10.1016/j.cell.2017.06.028.

Abstract

Spinal muscular atrophy (SMA) is caused by deficiency of SMN protein, which is crucial for spliceosome subunits biogenesis. Most SMA patients have SMN1 deletions, leaving SMN2 as sole SMN source; however, a C→T substitution converts an exonic-splicing enhancer (ESE) to a silencer (ESS), causing frequent exon7 skipping in SMN2 pre-mRNA and yielding a truncated protein. Antisense treatment to SMN2 intron7-splicing silencer (ISS) improves SMN expression and motor function. To view this Bench to Bedside, open or download the PDF.

MeSH terms

  • Humans
  • Muscular Atrophy, Spinal / genetics*
  • Muscular Atrophy, Spinal / therapy*
  • Oligonucleotides / therapeutic use*
  • Oligonucleotides, Antisense / therapeutic use*
  • RNA Splicing
  • Survival of Motor Neuron 2 Protein / genetics

Substances

  • Oligonucleotides
  • Oligonucleotides, Antisense
  • SMN2 protein, human
  • Survival of Motor Neuron 2 Protein
  • nusinersen